» Articles » PMID: 29922171

High Mobility Group Box 1 Promotes Aortic Calcification in Chronic Kidney Disease Via the Wnt/β-Catenin Pathway

Overview
Journal Front Physiol
Date 2018 Jun 21
PMID 29922171
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular calcification (VC) is common in chronic kidney disease (CKD), where cardiovascular mortality remains the leading cause of death. Here, we examined the role of high-mobility group box1 (HMGB1), a nuclear DNA-binding protein involved in inflammation, in aortic calcification and renal dysfunction induced by high phosphate in a mouse model of CKD induced by 5/6 nephrectomy. HMGB1 and kidney function markers were measured by ELISA in the serum of CKD patients and in CKD mice. Sections of the aortas of mice were analyzed by immunofluorescence and Alizarin red staining, and protein lysates were generated to analyze the expression of related proteins in response to silencing of HMGB1 or β-catenin by western blotting. Our results showed that serum HMGB1 levels were significantly higher in CKD patients than in healthy controls and related to disease stage. High phosphate promoted the translocation of HMGB1 from the nucleus to the cytosol and aortic calcification in CKD mice , whereas HMGB1 knockdown ameliorated part of renal and vascular function. β-catenin silencing reversed high phosphate-induced calcification and restored renal marker levels. Taken together, our results suggest that HMGB1 is involved in VC associated with CKD via a mechanism involving the β-catenin.

Citing Articles

High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies.

Datta S, Rahman M, Koka S, Boini K Cells. 2024; 13(23).

PMID: 39682695 PMC: 11639863. DOI: 10.3390/cells13231946.


HMGB1 Modulates High Glucose-Induced Erroneous Differentiation of Tendon Stem/Progenitor Cells through RAGE/-Catenin Pathway.

Lu P, Dai G, Shi L, Li Y, Zhang M, Wang H Stem Cells Int. 2024; 2024:2335270.

PMID: 38633380 PMC: 11022503. DOI: 10.1155/2024/2335270.


Serum high mobility group box 1 as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes.

Liu T, Zhao H, Wang Y, Qu P, Wang Y, Wu X Front Immunol. 2024; 15:1334109.

PMID: 38481996 PMC: 10932975. DOI: 10.3389/fimmu.2024.1334109.


Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease.

Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P Int J Biol Sci. 2023; 19(15):5020-5035.

PMID: 37781525 PMC: 10539693. DOI: 10.7150/ijbs.87964.


Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis.

Xie Z, Tong S, Chu X, Feng T, Geng M Kidney Dis (Basel). 2022; 8(4):275-285.

PMID: 36157262 PMC: 9386403. DOI: 10.1159/000524475.


References
1.
Chen Q, Guan X, Zuo X, Wang J, Yin W . The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm Sin B. 2016; 6(3):183-8. PMC: 4856949. DOI: 10.1016/j.apsb.2016.02.004. View

2.
Vattikuti R, Towler D . Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004; 286(5):E686-96. DOI: 10.1152/ajpendo.00552.2003. View

3.
Demer L, Tintut Y . Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008; 117(22):2938-48. PMC: 4431628. DOI: 10.1161/CIRCULATIONAHA.107.743161. View

4.
Andersson U, Antoine D, Tracey K . The functions of HMGB1 depend on molecular localization and post-translational modifications. J Intern Med. 2014; 276(5):420-4. DOI: 10.1111/joim.12309. View

5.
Jono S, McKee M, Murry C, Shioi A, Nishizawa Y, Mori K . Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-7. DOI: 10.1161/01.res.87.7.e10. View